SHIFTBIO Trademark

Trademark Overview

On Thursday, December 16, 2021, a trademark application was filed for SHIFTBIO with the United States Patent and Trademark Office. The USPTO has given the SHIFTBIO trademark a serial number of 97175909. The federal status of this trademark filing is REGISTERED as of Tuesday, July 9, 2024. This trademark is owned by SHIFTBIO. The SHIFTBIO trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Biopharmaceutical research and development services related to new drug modalities in particular exosomes
shiftbio

General Information

Serial Number97175909
Word MarkSHIFTBIO
Filing DateThursday, December 16, 2021
Status700 - REGISTERED
Status DateTuesday, July 9, 2024
Registration Number7444068
Registration DateTuesday, July 9, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 22, 2023

Trademark Statements

Pseudo MarkSHIFT BIO
Goods and ServicesBiopharmaceutical research and development services related to new drug modalities in particular exosomes

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, December 21, 2021
Primary Code042
First Use Anywhere DateSunday, November 1, 2020
First Use In Commerce DateSunday, November 1, 2020

Trademark Owner History

Party NameSHIFTBIO
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSeoul 02751
KR
Party NameSHIFTBIO
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeoul 02751
KR
Party NameSHIFTBIO
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeoul 02751
KR

Trademark Events

Event DateEvent Description
Tuesday, December 21, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, December 20, 2021NEW APPLICATION ENTERED
Thursday, September 22, 2022ASSIGNED TO EXAMINER
Thursday, September 22, 2022NON-FINAL ACTION WRITTEN
Thursday, September 22, 2022NON-FINAL ACTION E-MAILED
Thursday, September 22, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, March 21, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, March 21, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 22, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 19, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, August 22, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Wednesday, August 2, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 22, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 17, 2024USE AMENDMENT FILED
Wednesday, April 17, 2024TEAS STATEMENT OF USE RECEIVED
Tuesday, May 7, 2024CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, May 10, 2024STATEMENT OF USE PROCESSING COMPLETE
Tuesday, June 4, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, June 4, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, July 9, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, July 9, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, October 17, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Related Keywords

shiftbio modalities particular exosomes drug related research development services biopharmaceutical